| ORIGINAL ARTICLE |
|
| Year : 2020 | Volume
: 19
| Issue : 3 | Page : 260-265 |
|
|
An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay
Esmail Jafari1, Hojjat Ahmadzadehfar2, Habibollah Dadgar3, Majid Assadi1
1 Department of Molecular Imaging and Radionuclide Therapy, The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran
2 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
3 Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran
Correspondence Address:
Prof. Majid Assadi
The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr
Iran
  | Check |
DOI: 10.4103/wjnm.WJNM_78_19 
|
|
|
Prostate-specific membrane antigen (PSMA) is a Type II transmembrane glycoprotein which is extremely overexpressed in prostate cancer epithelial cells. Recently, PSMA-targeted small molecule labeled with68Ga and99mTc allowed precise molecular imaging of prostate cancer and PSMA-targeted small molecule labeled with 177Lu leads to the development of radionuclide-targeted therapy of prostate cancer. Despite its name, it has been shown that PSMA has been expressed in several malignancies which can be due to significant neovascularization. Present pictorial assay reports the nonspecific tracer uptake in some malignancies during68Ga-PSMA positron-emission tomography/computed tomography imaging and99mTc-PSMA scintigraphy. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Users Online: 654 
